Baillie Gifford & Co’s Lyell Immunopharma LYEL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-7,097
| Closed | -$196K | – | 279 |
|
|
2024
Q3 | $196K | Sell |
7,097
-18,903
| -73% | -$522K | ﹤0.01% | 264 |
|
|
2024
Q2 | $754K | Sell |
26,000
-6,808
| -21% | -$197K | ﹤0.01% | 260 |
|
|
2024
Q1 | $1.46M | Sell |
32,808
-1,736
| -5% | -$77.4K | ﹤0.01% | 252 |
|
|
2023
Q4 | $1.34M | Sell |
34,544
-2,088
| -6% | -$81K | ﹤0.01% | 256 |
|
|
2023
Q3 | $1.08M | Sell |
36,632
-1,434
| -4% | -$42.2K | ﹤0.01% | 263 |
|
|
2023
Q2 | $2.42M | Hold |
38,066
| – | – | ﹤0.01% | 251 |
|
|
2023
Q1 | $1.8M | Hold |
38,066
| – | – | ﹤0.01% | 256 |
|
|
2022
Q4 | $2.64M | Buy |
38,066
+311
| +0.8% | +$21.6K | ﹤0.01% | 257 |
|
|
2022
Q3 | $5.54M | Buy |
37,755
+2,372
| +7% | +$348K | 0.01% | 236 |
|
|
2022
Q2 | $4.62M | Sell |
35,383
-3,854
| -10% | -$503K | ﹤0.01% | 237 |
|
|
2022
Q1 | $3.96M | Buy |
39,237
+3,068
| +8% | +$310K | ﹤0.01% | 256 |
|
|
2021
Q4 | $5.6M | Buy |
36,169
+14,795
| +69% | +$2.29M | ﹤0.01% | 260 |
|
|
2021
Q3 | $6.33M | Buy |
21,374
+8,433
| +65% | +$2.5M | ﹤0.01% | 256 |
|
|
2021
Q2 | $4.2M | Buy |
+12,941
| New | +$4.2M | ﹤0.01% | 260 |
|